Latin America Benign Prostatic Hyperplasia Treatment Market Size 2034

Latin America Benign Prostatic Hyperplasia Treatment Market Size

Latin America Benign Prostatic Hyperplasia Treatment Market size is projected at USD 895.24 million in 2026 and is expected to hit USD 1,379.87 million by 2034 with a CAGR of 5.8%. The 2025 country-market baseline stood at USD 848.12 million, indicating an increase of USD 47.12 million into 2026. Market assessment requires country-level demand mapping, treatment segmentation, patient access analysis, technology adoption assessment, and evaluation of the competitive landscape across pharmaceutical and procedural BPH therapies.

Key Takeaways

Dominant country:Brazil accounts for approximately39.1%of the supplied 2026 country total, representingUSD 350.27 million, and is forecast to reachUSD 530.67 million by 2034at5.33% CAGR.
Fastest-growing country:Chile records the highest country CAGR at5.80%, increasing fromUSD 71.16 million in 2026toUSD 111.72 million by 2034.
Dominant treatment:Pharmacological treatment represents approximately47.5%of the supplied 2026 treatment total, valued atUSD 425.40 million, and is forecast atUSD 664.34 million by 2034.
Fastest-growing treatment:Pharmacological treatment also records the highest treatment-category CAGR at5.73%, ahead of surgical treatment at5.64%and minimally invasive procedures at5.61%.
Emerging country:Argentina is projected to advance fromUSD 155.27 million in 2026toUSD 243.02 million in 2034, registering a5.76% CAGR.

The market encompasses pharmacological therapies, conventional surgical interventions, minimally invasive procedures, and conservative approaches used to manage lower urinary tract symptoms associated with benign prostate enlargement. Based on the supplied treatment dataset, pharmacological treatment contributes 47.5% of 2026 value, compared with 27.2% for surgical treatment, 15.3% for minimally invasive procedures, and 10.0% for other treatments. Brazil contributes 39.1% of the supplied country total, Mexico 28.6%, Argentina 17.3%, Chile 7.9%, and Colombia 7.0%. Historical epidemiological research reported approximately 1.81 million prevalent BPH cases in Brazil in 2019, nearly 98.6% above the corresponding 2000 burden, supporting a substantial addressable treatment population.

Source: Company Publications, Primary Interviews, and skymarketinsights Analysis

Explore more data points, trends and opportunities Download Free Sample Report

Latin America Benign Prostatic Hyperplasia Treatment Market Trends

Shift Toward Minimally Invasive, Function-Preserving BPH Intervention

Clinical practice is progressively expanding beyond long-duration drug therapy and conventional tissue-resection surgery toward minimally invasive technologies designed to shorten procedures and preserve sexual function. Rezūm delivers controlled water-vapor energy into obstructive prostate tissue, with reported procedure time of 5.3 ± 3.5 minutes, 10.4-point sustained IPSS improvement and a 4.4% surgical retreatment rate through five years. These performance indicators strengthen technology adoption among patients seeking alternatives to chronic medication or conventional surgery.

Comparative evidence is further intensifying technology competition. A 2024 analysis covering 148 patients, including 80 Rezūm and 68 UroLift recipients, reported mean symptom-score improvement of 58.29% following Rezūm versus 44.53% following UroLift. Separately, a systematic review evaluated 32 studies, including 10 randomized trials, 22 prospective cohorts, and approximately 2,400 participants across newer BPH interventions. These volumes illustrate the expanding evidence base supporting minimally invasive therapy selection.

Latin America Benign Prostatic Hyperplasia Treatment Market Drivers

Ageing Male Population and Persistent Symptomatic Treatment Requirements

Demographic ageing, increasing diagnosis of lower urinary tract symptoms, and broader availability of urology services are expanding treatment requirements. Historical disease-burden evidence showed Brazilian BPH prevalence increasing from approximately 912,000 cases in 2000 to 1.81 million in 2019, a 98.6% increase, while age-standardized prevalence was approximately 1,730 per 100,000 population in 2019. Pharmacological therapy remains a first-line pathway, while persistent symptoms, urinary retention, medication intolerance, and quality-of-life deterioration create downstream procedural demand.

Latin America Benign Prostatic Hyperplasia Treatment Market Restraints

Treatment Trade-offs, Retreatment Risk and Unequal Access to Advanced Procedures

Clinical trade-offs between symptom improvement, sexual-function preservation, recovery time, and durability can delay procedural decisions. Evidence covering 2,400 patients across 32 studies demonstrates that retreatment remains an important consideration for newer interventions, while the studied population had a median age of 66 years, median prostate volume of 51.9 mL, and median IPSS of 22. Unequal access to specialized urologists, laser platforms and minimally invasive systems can additionally reinforce dependence on medication and established procedures.

Latin America Benign Prostatic Hyperplasia Treatment Market Opportunities

Expansion of Office-Based and Function-Preserving Therapies

Office-oriented and minimally invasive therapies provide an opportunity to address patients positioned between medication and conventional surgery. Rezūm has demonstrated clinically significant improvements through 5 years, with 5.3 ± 3.5-minute procedure time and 4.4% five-year surgical retreatment. Meanwhile, comparative clinical research reported post-treatment mean AUA symptom scores of 9.83 for Rezūm and 13.37 for UroLift, supporting continued competition around symptom relief, convenience, recovery and preservation of sexual function.

Challenges in Latin America Benign Prostatic Hyperplasia Treatment Market

Balancing Clinical Durability, Patient Selection and Technology Economics

Providers must select therapies across heterogeneous prostate sizes, symptom severity and patient preferences while managing equipment and training requirements. A multicenter real-world analysis published in 2025 compared Rezūm and UroLift using electronic health records extending from 2014 through June 2024, illustrating the growing emphasis on long-term reintervention outcomes. Another 2025 dataset initially identified 9,145 UroLift and 4,477 Rezūm patients across 90 and 79 healthcare organizations, respectively, demonstrating both expanding utilization and the need for outcome-based technology selection.

Report Scope

Report Metric	Details
Market Size in 2025	USD 848.12 Million
Market Size in 2026	USD 895.24 Million
Market Size in 2034	USD 1379.87 Million
CAGR	5.8% (2026-2034)
Base Year for Estimation	2025
Historical Data	2022-2024
Forecast Period	2026-2034
Report Coverage	Revenue Forecast, Competitive Landscape, Supply Chain Disruption, Growth Factors, Environment & Regulatory Landscape and Trends

Explore more data points, trends and opportunities Download Free Sample Report

Latin America Benign Prostatic Hyperplasia Treatment Market Segmentation

Treatment segmentation comprises pharmacological treatment, surgical treatment, minimally invasive procedures and other treatments. Pharmacological therapy dominates with approximately 47.5% of the supplied 2026 treatment total, followed by surgery at 27.2%, minimally invasive procedures at 15.3%, and other treatments at 10.0%.

By Treatment Type

Pharmacological treatment is the largest category, rising from USD 402.35 million in 2025 to USD 425.40 million in 2026 and USD 664.34 million by 2034, representing a 5.73% CAGR. It includes alpha-blockers such as tamsulosin, silodosin, alfuzosin and doxazosin; 5-ARIs including dutasteride and finasteride; combination therapies; PDE5 inhibitors; and herbal or other drugs.

Pharmacological treatment is also the fastest-growing supplied treatment category at 5.73% CAGR. Surgical treatment increases from USD 243.43 million in 2026 to USD 377.57 million by 2034 at 5.64%, while minimally invasive procedures advance from USD 137.40 million to USD 212.63 million at 5.61%. Other treatments rise from USD 89.93 million to USD 138.01 million, registering 5.50% CAGR.

By End Use

Hospitals, clinics, ambulatory surgical centres and specialty urology centers constitute the end-use structure. The supplied numerical tables do not allocate the USD 896.16 million 2026 treatment total among these end users; therefore, unsupported end-use values are not introduced.

Demand nevertheless spans medication management, diagnostic follow-up and procedural care, with minimally invasive and surgical treatment together representing approximately 42.5% of the supplied 2026 treatment value. This creates substantial procedural relevance for hospitals, ambulatory facilities and specialist urology centers.

By Patient Age Group

Patient segmentation comprises below 50 years, 50–60 years, and above 60 years. No age-group revenue split or CAGR is supplied, so numerical allocation is not fabricated. Clinical literature on newer BPH interventions reports a median patient age of approximately 66 years, indicating the importance of older men in procedural populations.

Age-related prostate enlargement and increasing symptom severity support higher intervention intensity among older populations. In the comparative Rezūm-UroLift study, average patient ages were 67.55 years and 71.79 years, respectively.

By Distribution Channel

Distribution channels comprise hospital pharmacy, retail pharmacy and online pharmacy. Pharmacological treatment represents approximately 47.5% of the supplied 2026 treatment total and reaches USD 664.34 million by 2034, creating a significant addressable pharmaceutical distribution requirement.

No separate hospital, retail or online pharmacy CAGR is provided in the mandatory dataset. Accordingly, the 5.73% CAGR applies only to the overall pharmacological treatment category and is not reassigned to individual distribution channels.

Latin America Benign Prostatic Hyperplasia Treatment Market Segmentations

By Treatment Type

Pharmacological treatment
- Alpha-blockers
- 5-alpha reductase inhibitors (5-ARI)
- Combination therapy
- Phosphodiesterase-5 inhibitors (pde5 inhibitors)
- Herbal and other drugs
Surgical treatment
- Transurethral resection of the prostate (TURP)
- Transurethral incision of the prostate (TUIP)
- Open prostatectomy
- Laser therapy
Minimally invasive procedures
- Urolift system
- RezÅ«m water vapour therapy
- Prostatic artery embolisation
- Microwave thermotherapy
- Transurethral needle ablation (TUNA)
Other treatments
- Lifestyle modifications
- Watchful waiting / active surveillance

By End Use

Hospitals
Clinics
Ambulatory surgical centres
Specialty urology centers

By Patient Age Group

Below 50 years
50–60 years
Above 60 years

By Distribution Channel

Hospital pharmacy
Retail pharmacy
Online pharmacy

Latin America Benign Prostatic Hyperplasia Treatment Market Counties Outlook

The requested UAE, Turkey, Saudi Arabia, South Africa, Egypt and Nigeria country set is geographically outside Latin America and is not contained in the mandatory Latin America dataset. Assigning Latin America revenue, contribution, production or forecast values to these countries would conflict with the supplied data. The valid Latin America country dataset instead comprises Brazil, Mexico, Argentina, Colombia and Chile.

Brazil

Brazil leads with USD 350.27 million in 2026, approximately 39.1% of the supplied country total, and reaches USD 530.67 million by 2034 at 5.33% CAGR. Its 2025 baseline is USD 332.55 million.

Mexico

Mexico contributes approximately 28.6%, with value increasing from USD 255.80 million in 2026 to USD 397.96 million in 2034, representing 5.68% CAGR and a 2025 baseline of USD 242.05 million.

Argentina

Argentina represents approximately 17.3% of the supplied 2026 country total. Value advances from USD 155.27 million to USD 243.02 million by 2034, registering 5.76% CAGR.

Colombia

Colombia accounts for approximately 7.0% in 2026, valued at USD 62.74 million versus USD 59.45 million in 2025. It is forecast to reach USD 96.50 million by 2034 at 5.53% CAGR.

Chile

Chile contributes approximately 7.9% in 2026 and records the fastest supplied country CAGR at 5.80%. Value increases from USD 71.16 million in 2026 to USD 111.72 million in 2034.

Regional Growth Insights Download Free Sample

Top players in Latin American benign prostatic hyperplasia treatment market

Boston Scientific Corporation
Teleflex Incorporated
Olympus Corporation
KARL STORZ SE & Co. KG
Richard Wolf GmbH
Cook Medical
Medtronic plc
Johnson & Johnson
Astellas Pharma Inc.
GSK plc
Sanofi
Viatris Inc.
Boehringer Ingelheim
Bayer AG
Terumo Corporation

Top Two Companies

Boston Scientific Corporation:A company-specific Latin America percentage is not disclosed in the supplied dataset, so no unsupported share is assigned. The company holds a notable technology position through Rezūm water-vapor therapy, which uses controlled convective thermal energy. Published product evidence reports10.4-point IPSS improvementmaintained through5 years, procedure time of5.3 ± 3.5 minutes, and a4.4% surgical retreatment ratethrough five years. These metrics position the platform within the minimally invasive segment, which represents approximately15.3%of supplied 2026 treatment value.
Teleflex Incorporated:No verified company-specific Latin America percentage is contained in the mandatory dataset, preventing responsible assignment of a numerical company share. Teleflex competes through the UroLift System, a minimally invasive prostatic urethral lift technology. In2025, the company highlighted two randomized head-to-head trials comparing UroLift with Rezūm and tamsulosin, alongside an analysis using the AUA Quality Registry. Its positioning is particularly relevant as minimally invasive procedures are forecast to increase fromUSD 137.40 million in 2026toUSD 212.63 million by 2034.

Recent Developments in the Latin America Benign Prostatic Hyperplasia Treatment Market

2025: Teleflex presented new UroLift clinical evidence from 2 randomized head-to-head trials at the American Urological Association Annual Meeting, including comparisons with Rezūm and tamsulosin.
2025: A multicenter propensity-matched study evaluated the durability and reintervention profiles of Rezūm and UroLift using records extending through June 2024.
2025: Real-world research comparing sexual-function outcomes initially evaluated 9,145 UroLift and 4,477 Rezūm recipients across dozens of healthcare organizations.

Research Methodology

The assessment applies a structured combination of supplied quantitative market data and secondary clinical evidence. The mandatory tables serve as the primary source for 2025, 2026 and 2034 values, country contributions, treatment contributions and CAGRs. Country percentages are calculated from the supplied USD 895.24 million 2026 country total, while treatment percentages are calculated independently from the supplied USD 896.16 million treatment total. The source tables therefore contain a USD 0.92 million difference between their respective 2026 totals and a USD 12.68 million difference between their 2034 totals; both datasets have been retained without alteration. Secondary research is used only for epidemiology, clinical technology, procedure volumes and recent developments, while unsupported segment, country and company-share estimates are excluded.

Frequently Asked Questions

What is the Latin America Benign Prostatic Hyperplasia Treatment Market size in 2026?

The Latin America Benign Prostatic Hyperplasia Treatment Market is projected to reach USD 895.24 million in 2026.

What is the forecast size of the Latin America Benign Prostatic Hyperplasia Treatment Market by 2034?

The Latin America Benign Prostatic Hyperplasia Treatment Market is expected to reach USD 1,379.87 million by 2034.

What is the CAGR of the Latin America Benign Prostatic Hyperplasia Treatment Market from 2026 to 2034?

The Latin America Benign Prostatic Hyperplasia Treatment Market is projected to grow at a CAGR of 5.8% from 2026 to 2034.

Which segment dominates the Latin America Benign Prostatic Hyperplasia Treatment Market?

Pharmacological treatment dominates the treatment segment with USD 425.40 million in 2026, representing approximately 47.5% of the treatment-type total. It is also the fastest-growing treatment category at a 5.73% CAGR.

Who are the top players in the Latin America Benign Prostatic Hyperplasia Treatment Market?

Top players include Boston Scientific Corporation, Teleflex Incorporated, Olympus Corporation, KARL STORZ SE & Co. KG, Richard Wolf GmbH, Cook Medical, Medtronic plc, Johnson & Johnson, Astellas Pharma Inc., GSK plc, Sanofi, Viatris Inc., Boehringer Ingelheim, Bayer AG, and Terumo Corporation.

Author: Jenny Burkett

Senior Market Research Analyst | 8 Years Experience | Digital Therapeutics and Connected Medical Devices

Jenny specializes in digital therapeutics, remote monitoring devices and healthcare IT platforms. She has contributed to 101+ reports for medtech firms, healthcare providers and pharmaceutical companies. Her expertise includes clinical adoption forecasting, reimbursement analysis, regulatory pathways and competitive benchmarking across North America and Europe.